Omega Therapeutics Inc is a biotechnology company focused on developing and commercializing a new class of therapies known as epigenetic modulators
These innovative treatments aim to control gene expression and potentially address a range of diseases, including cancers and other serious health conditions. By leveraging their proprietary technology platform, Omega seeks to create precise and targeted therapies that can improve patient outcomes while minimizing side effects. The company is dedicated to advancing its research and development efforts to bring transformative solutions to the healthcare market.
CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a biotechnology company pioneering the development of a new class of programmable epigenomic medicines, today announced financial results for the quarter ended September 30, 2024 and multiple strategic and leadership updates, including the appointment of Kaan Certel, Ph.D., an industry veteran with extensive experience in corporate strategy and business development, as Chief Executive Officer. Dr. Certel succeeds Mahesh Karande as CEO, who has decided to leave Omega for personal reasons. In addition, the Company shared updated clinical data from the Phase 1 MYCHELANGELO™ I clinical trial and a strategic prioritization of its pipeline to focus resources on programs in which the Company believes epigenomic controllers have the potential to demonstrate therapeutic advantages over existing modalities, address significant unmet needs and unlock rapid value creation.
CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced it will share new preclinical data at three upcoming scientific meetings.
CAMBRIDGE, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the publication of preclinical data from studies of OTX-2002 in Nature Communications. The article highlights the potential of Omega’s approach to precision epigenomic control and the ability of OTX-2002 to controllably regulate the historically undruggable MYC gene in multiple models of hepatocellular carcinoma (HCC), the most common type of primary liver cancer.
CAMBRIDGE, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the addition of Jennifer Nelson, Ph.D., to the Company’s executive leadership team in the role of Senior Vice President of Research. She brings over 20 years of experience working with RNA- and DNA-based therapies and technologies, and extensive expertise as a leader in building novel platforms.
CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced financial results for the second quarter ended June 30, 2024, and highlighted recent Company progress.
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will participate in fireside chats at two upcoming investor conferences.
CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the appointment of Kaan Certel, Ph.D., as Chief Business Officer. Dr. Certel brings to Omega extensive biopharmaceutical industry experience and will be responsible for global business development activities including strategic partnerships.
CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the presentation of new preclinical data demonstrating durable and tunable bidirectional regulation of gene expression in cellular models at the pre-transcriptional level at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, taking place in Baltimore, Maryland, May 7 – 11.
CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced financial results for the first quarter ended March 31, 2024, and highlighted recent Company progress.
CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced it will present a poster at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking place in Baltimore, MD, May 7 – 11, 2024. The poster will feature new preclinical data that demonstrate the ability of Omega's programmable epigenomic controllers (ECs) to pre-transcriptionally upregulate gene expression across a diverse set of genes, offering a broad range of potential therapeutic applications.
